Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028652 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00028652: Clinical Trial Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT00028652 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028652, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating patients who have skin metastases.
Interventions
- BIOLOGICAL interleukin-12 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Phase | Phase 1 |
Why NCT00028652 stopped before completion
NCT00028652 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which interleukin-12 gene is the first listed.
NCT00028652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00028652 about?
NCT00028652 is a clinical study titled "Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases". RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating patients who have skin metastases.
What is the current status of trial NCT00028652?
This trial is currently terminated. It is a Phase 1 study. The study started on 2002-01.
What interventions are being tested in trial NCT00028652?
The interventions under investigation include: interleukin-12 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00028652?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia